TY - JOUR
T1 - Laboratory study of NY-198 and clinical evaluation in respiratory tract infections
AU - Aonuma, Seiichi
AU - Tokue, Yutaka
AU - Kitamura, Naoto
AU - Honda, Yoshihiro
AU - Ono, Reiko
AU - Watanabe, Akira
AU - Ohizumi, Kohtaro
AU - Konno, Kiyoshi
AU - Nagai, Kohsaku
PY - 1988/1/1
Y1 - 1988/1/1
N2 - We examined the in vitro antimicrobial activity of NY-198, a newly developed quinolone derivative by the broth-dilution method using an MIC-2000 system, and compared minimum inhibitory concentrations (MICs) of NY-198 against 170 clinical isolates with those of norfloxacin (NFLX), ofloxacin (OFLX) and ciprofloxacin (CPFX). Against S. aureus, NY-198 was less active than CPFX and OFLX but more active than NFLX. However, against all other isolates tested (E. colt, K. pneumoniae, S. marcescens, E. cloacae, P. mirabilis, M. morganii, P. vulgaris and P. aeruginosa) NY-198 was less active than CPFX and NFLX, and nearly as active as OFLX. Thirty-four patients suffering from respiratory tract infection received orally 400 or 600 mg of NY-198 a day. Clinical response was excellent in 2, good in 19, fair in 4, and poor in 8; 1 was not evaluated. Dizziness was observed in two and anorexia with fatiguability in one patient. No abnormalities in laboratory findings were observed.
AB - We examined the in vitro antimicrobial activity of NY-198, a newly developed quinolone derivative by the broth-dilution method using an MIC-2000 system, and compared minimum inhibitory concentrations (MICs) of NY-198 against 170 clinical isolates with those of norfloxacin (NFLX), ofloxacin (OFLX) and ciprofloxacin (CPFX). Against S. aureus, NY-198 was less active than CPFX and OFLX but more active than NFLX. However, against all other isolates tested (E. colt, K. pneumoniae, S. marcescens, E. cloacae, P. mirabilis, M. morganii, P. vulgaris and P. aeruginosa) NY-198 was less active than CPFX and NFLX, and nearly as active as OFLX. Thirty-four patients suffering from respiratory tract infection received orally 400 or 600 mg of NY-198 a day. Clinical response was excellent in 2, good in 19, fair in 4, and poor in 8; 1 was not evaluated. Dizziness was observed in two and anorexia with fatiguability in one patient. No abnormalities in laboratory findings were observed.
UR - http://www.scopus.com/inward/record.url?scp=85004281843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85004281843&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.36.Supplement2-Clinical_486
DO - 10.11250/chemotherapy1953.36.Supplement2-Clinical_486
M3 - Article
AN - SCOPUS:85004281843
VL - 36
SP - 486
EP - 494
JO - CHEMOTHERAPY
JF - CHEMOTHERAPY
SN - 0009-3165
ER -
